The 36-month beta value for CTXR is at 1.63. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTXR is 168.40M, and currently, shorts hold a 7.95% of that float. The average trading volume for CTXR on September 19, 2024 was 2.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTXR) stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR)’s stock price has increased by 3.47 compared to its previous closing price of 0.51. However, the company has seen a 1.97% increase in its stock price over the last five trading sessions. prnewswire.com reported 2024-09-05 that CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C.
CTXR’s Market Performance
CTXR’s stock has risen by 1.97% in the past week, with a monthly drop of -12.53% and a quarterly drop of -17.61%. The volatility ratio for the week is 5.18% while the volatility levels for the last 30 days are 7.88% for Citius Pharmaceuticals Inc The simple moving average for the last 20 days is -4.63% for CTXR stock, with a simple moving average of -26.91% for the last 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at -25.59% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.68% of loss for the given period.
Volatility was left at 7.88%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares sank -10.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.26% lower at present.
During the last 5 trading sessions, CTXR rose by +3.38%, which changed the moving average for the period of 200-days by -30.79% in comparison to the 20-day moving average, which settled at $0.5502. In addition, Citius Pharmaceuticals Inc saw -30.24% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTXR
The total capital return value is set at -0.44. Equity return is now at value -41.76, with -36.91 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -90.9. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -10.01.
Currently, EBITDA for the company is -36.54 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.75.
Conclusion
In conclusion, Citius Pharmaceuticals Inc (CTXR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
